2noa
From Proteopedia
Line 1: | Line 1: | ||
[[Image:2noa.gif|left|200px]] | [[Image:2noa.gif|left|200px]] | ||
- | + | <!-- | |
- | + | The line below this paragraph, containing "STRUCTURE_2noa", creates the "Structure Box" on the page. | |
- | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
- | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
- | + | or leave the SCENE parameter empty for the default display. | |
- | | | + | --> |
- | | | + | {{STRUCTURE_2noa| PDB=2noa | SCENE= }} |
- | + | ||
- | + | ||
- | }} | + | |
'''The structure of deoxycytidine kinase complexed with lamivudine and ADP.''' | '''The structure of deoxycytidine kinase complexed with lamivudine and ADP.''' | ||
Line 29: | Line 26: | ||
[[Category: Sabini, E.]] | [[Category: Sabini, E.]] | ||
[[Category: 3tc]] | [[Category: 3tc]] | ||
- | [[Category: | + | [[Category: Antiviral]] |
- | [[Category: | + | [[Category: Dck]] |
- | [[Category: | + | [[Category: Enantiomer]] |
- | [[Category: | + | [[Category: Epivir]] |
- | [[Category: | + | [[Category: Human deoxycytidine kinase]] |
- | [[Category: | + | [[Category: L-dc]] |
- | [[Category: | + | [[Category: Lamivudine]] |
- | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 09:42:02 2008'' | |
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + |
Revision as of 06:42, 4 May 2008
The structure of deoxycytidine kinase complexed with lamivudine and ADP.
Overview
L-nucleoside analogs represent an important class of small molecules for treating both viral infections and cancers. These pro-drugs achieve pharmacological activity only after enzyme-catalyzed conversion to their tri-phosphorylated forms. Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent. The first step in activating these agents is catalyzed by dCK. Our studies reveal how dCK, which normally catalyzes phosphorylation of the natural D-nucleosides, can efficiently phosphorylate substrates with non-physiologic chirality. The capability of dCK to phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of both the enzyme and the substrates themselves. First, the nucleoside-binding site tolerates substrates with different chiral configurations by maintaining virtually all of the protein-ligand interactions responsible for productive substrate positioning. Second, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformational flexibility allows the L- and D-enantiomeric forms to adopt similar shapes when bound to the enzyme. This is the first analysis of the structural basis for activation of L-nucleoside analogs, providing further impetus for discovery and clinical development of new agents in this molecular class.
About this Structure
2NOA is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase., Sabini E, Hazra S, Konrad M, Burley SK, Lavie A, Nucleic Acids Res. 2007;35(1):186-92. Epub 2006 Dec 7. PMID:17158155 Page seeded by OCA on Sun May 4 09:42:02 2008
Categories: Deoxycytidine kinase | Homo sapiens | Single protein | Lavie, A. | Sabini, E. | 3tc | Antiviral | Dck | Enantiomer | Epivir | Human deoxycytidine kinase | L-dc | Lamivudine